Saama Appoints Susan Atkinson, Ph.D. as Advisor

CAMPBELL, Calif. – Today, life sciences solutions company Saama announced that Susan Atkinson, Ph.D., has joined the company as Advisor.

In this role, Susan will use her decades of experience in clinical trials, research and development, and pharmaceuticals to support Saama’s evolution in data and analytics innovation.

“Susan’s expertise, leadership, and expansive skill set will serve Saama well as we continue to devise innovative life sciences solutions,” said Vivek Sharma, Chief Executive Officer of Saama. “We are thrilled to welcome Susan as an Advisor and confident that her decades of experience will prove indispensable in supporting our continued evolution.” 

Susan Atkinson boasts over 35 years of expertise in clinical trials and research and development, having served as a pharmaceutical industry executive for decades.  As founder of AtCure Consulting, she brings a wealth of knowledge to her practice as she consults with technology companies, biotechnology firms, CROs, and private equity firms investing in the health care sector.   

Previously, Susan led PPD Inc. (Pharmaceutical Product Development), a global organization, as Senior Vice President of Global Biometrics and Centralized Services during her 30-year tenure. Her leadership skills span diverse functions, from core biostatistics and programming to data management, clinical supplies and logistics, clinical development technologies, and process improvement. Susan’s proven track record and exceptional professional experience position her well to support Saama’s journey in data and analytics innovation. 

A board member for Everest Clinical Research, Susan is also involved in nonprofit board work and volunteer roles in the community. 

She earned her Ph.D. in Biostatistics from the School of Public Health at the University of North Carolina at Chapel Hill.

About Saama

Saama develops life science solutions that accelerate clinical and commercial development. Today, more than 50 biotech companies—including many of the top 20 pharmaceutical companies—use Saama’s award-winning Life Science Analytics Cloud (LSAC) platform to accelerate more than 1,500 studies, including the clinical trial that led to the world’s first COVID-19 vaccine. LSAC’s rich applications facilitate unprecedented and authoritative oversight and automation of comprehensive clinical research data, enabling companies to file New Drug Applications (NDAs) more efficiently and bring treatments to patients sooner. Discover more at and follow @SaamaTechInc on Twitter.


.spacing br + br {
display: none !important;

Victoria Clayton
Gregory FCA
[email protected]